Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis

The Lancet Respiratory Medicine

Volumn 5, Issue 1, 2017, Pages 33-41

  Nathan, Steven D ^a   Albera, Carlo ^b   Bradford, Williamson Z ^c   Costabel, Ulrich ^d   Glaspole, Ian ^e   Glassberg, Marilyn K ^f   Kardatzke, David R ^g   Daigl, Monica ^h   Kirchgaessler, Klaus Uwe ^h   Lancaster, Lisa H ⁱ   Lederer, David J ^j   Pereira, Carlos A ^k   Swigris, Jeffrey J ^l   Valeyre, Dominique ^m   Noble, Paul W ⁿ  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c InterMune   (United States)

^d RUHRLANDKLINIK   (Germany)

^e ALFRED HOSPITAL   (Australia)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g GENENTECH INC   (United States)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^j Department of Medicine   (United States)

^k FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^l DEPARTMENT OF MEDICINE   (United States)

^m AVICENNE HOSPITAL   (France)

ⁿ CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; PLACEBO; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ARTICLE; CAUSE OF DEATH; DRUG EFFICACY; DRUG SAFETY; FIBROSING ALVEOLITIS; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; DRUG EFFECTS; MORTALITY; TREATMENT OUTCOME; VITAL CAPACITY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAUSE OF DEATH; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 85006314787     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30326-5     Document Type: Article

References (20)

1. 1 Raghu, G, Collard, HR, Egan, JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183 (2011), 788–824.
2. 2 Daniil, ZD, Gilchrist, FC, Nicholson, AG, et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 160 (1999), 899–905.
3. 3 Nicholson, AG, Colby, TV, du Bois, RM, Hansell, DM, Wells, AU, The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 162 (2000), 2213–2217.
4. 4 Taniguchi, H, Ebina, M, Kondoh, Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35 (2010), 821–829.
5. 5 Noble, PW, Albera, C, Bradford, WZ, et al., for the CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377 (2011), 1760–1769.
6. 6 King, TE Jr, Bradford, WZ, Castro-Bernardini, S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2083–2092.
7. 7 Azuma, A, Nukiwa, T, Tsuboi, E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171 (2005), 1040–1047.
8. 8 King, TE Jr, Albera, C, Bradford, WZ, et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med 189 (2014), 825–831.
9. 9 DerSimonian, R, Kacker, R, Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28 (2007), 105–114.
10. 10 Spiegelhalter, DJ, Abrams, KR, Myles, JP, Bayesian approaches to clinical trials and health-care evaluation, 2004, Wiley, London.
11. 11 Turner, RM, Davey, J, Clarke, MJ, Thompson, SG, Higgins, JP, Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol 41 (2012), 818–827.
12. 12 Noble, PW, Albera, C, Bradford, WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J 47 (2016), 243–253.
13. 13 Genentech. Esbriet (pirfenidone) capsules, for oral use. https://www.gene.com/download/pdf/esbriet_prescribing.pdf (accessed Nov 11, 2016).
14. 14 Raghu, G, Collard, HR, Anstrom, KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 185 (2012), 1044–1048.
15. 15 Bradford, WZ, Cohen, AH, Leff, JA, Selection of clinically meaningful primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 187 (2013), 1269–1270.
16. 16 Wells, AU, Behr, J, Costabel, U, et al. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax 67 (2012), 938–940.
17. 17 Blettner, M, Sauerbrei, W, Schlehofer, B, Scheuchenpflug, T, Friedenreich, C, Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol 28 (1999), 1–9.
18. 18 Bravata, DM, Olkin, I, Simple pooling versus combining in meta-analysis. Eval Health Prof 24 (2001), 218–230.
19. 19 Raghu, G, Rochwerg, B, Zhang, Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 192 (2015), e3–19.
20. 20 Nathan, SD, Shlobin, OA, Weir, N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 140 (2011), 221–229.